P653: OUTCOMES FOLLOWING TREATMENT WITH A COVALENT BTK AND BCL2 INHIBITOR AMONG PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): A REAL-WORLD STUDY OF A LARGE U.S. DATABASE

• T. A. Eyre,
• L. Hess,
• T. Sugihara,
• R. A. Walgren,
• P. B. Abada,
• H. Konig,
• J. Pagel,
• L. E. Roeker,
• A. Mato

Affiliations

T. A. Eyre

1 Oxford University Hospitals, NHS Foundation Trust, Oxford, United Kingdom

L. Hess

2 Eli Lilly and Company, Indianapolis

T. Sugihara

3 Syneos Health, Austin

R. A. Walgren

2 Eli Lilly and Company, Indianapolis

P. B. Abada

2 Eli Lilly and Company, Indianapolis

H. Konig

2 Eli Lilly and Company, Indianapolis

J. Pagel

4 Loxo Oncology, Stamford

L. E. Roeker

5 Memorial Sloan Kettering Cancer Center, New York, United States of America

A. Mato

5 Memorial Sloan Kettering Cancer Center, New York, United States of America